Aspirin Improves Nonalcoholic Fatty Liver Disease and Atherosclerosis through Regulation of the PPARδ-AMPK-PGC-1α Pathway in Dyslipidemic Conditions

Figure 6

Concentrations of ATP and TNFα in the aorta and liver, and concentrations of mannose receptor and CCR2 in spleen from rabbits administered a cholesterol diet and aspirin. (a) ATP concentration in the aorta showed a tendency to increase in the aspirin-administered group than that of the cholesterol-diet group without aspirin. (b) ATP concentration in the liver was higher in the aspirin-administered group than that of the cholesterol-diet group without aspirin. (c) TNFα concentration in the aorta was lower in the aspirin-administered group than that of the cholesterol-diet group without aspirin. (d) TNFα concentration in the liver showed an increasing trend in the cholesterol-diet group than that of the control group; however, it was lower in the aspirin-administered group than that of the cholesterol-diet group without aspirin. (e) CCR2 concentration in the spleen was higher in the cholesterol-diet group than that of the control group; however, it was lower in the aspirin-administered group. (f) Mannose receptor concentration in the spleen was higher in the aspirin-administered group than that of the cholesterol-diet group without aspirin. The results are expressed as (). Values were statistically analyzed by unpaired -test or one-way ANOVA. An upper line on the three bars means one-way ANOVA analysis. All experiments were repeated three and over times. Meaning of indications: Ctrl means normal control rabbits administered with normal, C means rabbits fed with 1% cholesterol diet, and CA means rabbits administered with 1% cholesterol diet plus aspirin of 100 mg/kg/day. , , .

(a)

(b)

(c)

(d)

(e)

(f)